Edwards Lifesciences (EW)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
At a market value of $50.3B, Edwards Lifesciences's free cash flow of $1.3B (fiscal 2025) would need to grow about 13% a year for the stock to be worth today's price. That is close to what the company has delivered over the last 9 years.
Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from Edwards Lifesciences's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.
Fundamental grade
Five factors scored 1 to 9 from EW's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Edwards Lifesciences's 10-K filings. The deep dive has 15+ years, quarters and every line.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $5.2B | $4.5B | $5.0B | $5.4B | $6.1B |
| Net income | $1.5B | $1.5B | $1.4B | $4.2B | $1.1B |
| Free cash flow | $1.4B | $974M | $643M | $290M | $1.3B |
| EPS (diluted) | $2.38 | $2.44 | $2.30 | $6.97 | $1.83 |
| Operating margin | 32.3% | 33.6% | 26.1% | 25.3% | 20.8% |
Where the revenue comes from
Revenue by products, fiscal 2025.
Superinvestors who own EW
From each investor's latest 13F filing (what a 13F shows). 5 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| PRIMECAP Management PRIMECAP Management Co |
Trimmed | $308M | 0.18% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Trimmed | $132M | 0.05% | Q2 2026 |
| Ron Baron Baron Capital (BAMCO) |
Added | $21M | 0.03% | Q2 2026 |
| David Rolfe Wedgewood Partners |
Trimmed | $15M | 3.1% | Q2 2026 |
| Joel Greenblatt Gotham Asset Management |
Trimmed | $9M | 0.02% | Q2 2026 |
Insider buying
Open-market purchases by Edwards Lifesciences's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Mar 23, 2026 | Ro Khanna |
0 | $81.95 | — |
| Mar 23, 2026 | Ro Khanna |
0 | $81.95 | — |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when EW trades at or below it.
Free accounts get 3 price alerts. No card needed.
In the full deep dive
Questions
What growth does Edwards Lifesciences's stock price imply?
At a market value of $50.3B, Edwards Lifesciences would need its free cash flow to grow about 13% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 9 years its free cash flow grew 11% a year.
Are Edwards Lifesciences insiders buying the stock?
2 open-market insider purchases of EW in the last 12 months, from SEC Form 4 filings.
Which superinvestors own Edwards Lifesciences?
5 of the superinvestors Investingly tracks hold EW in their latest 13F, including PRIMECAP Management, Cliff Asness, Ron Baron.
Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.